Alphavirus replicon particles as candidate HIV vaccines. - Wikidata - awgldk - TriplyDB

Alphavirus replicon particles as candidate HIV vaccines.

Alphavirus replicon particles as candidate HIV vaccines.

http://www.wikidata.org/entity/Q34743830

about

A novel self-replicating chimeric lentivirus-like particle Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development Vaccines for Venezuelan equine encephalitis Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants Rapid generation of a mouse model for Middle East respiratory syndrome.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses Efficient generation of human iPSCs by a synthetic self-replicative RNA.Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats.Identification of cross-reactive norovirus CD4+ T cell epitopes Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses.Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles.Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.Alphavirus vectors for vaccine production and gene therapy.A call for replicating vector prime-protein boost strategies in HIV vaccine design.Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.Replicating and non-replicating viral vectors for vaccine development Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.Polyvalent AIDS vaccines.Acute infection with venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Self-replicating alphavirus RNA vaccines.RNA-based viral vectors.A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32.Viral vectors for vaccine applications.

P2860

Q24611993-C2CADD23-DF0E-4245-84B1-88CCFF1D03A0 Q24657762-BD232CD7-0BA8-4E52-BBD5-12A20E4B477E Q27477561-EC4DCC60-3AF1-4AC1-B75C-658DCA9F8BDA Q27490196-93285271-99CE-4854-A42A-BCF0C588F18D Q28394899-B8BE52B4-C4CD-4D7A-A472-EE97AEBED631 Q28764574-07A63319-B10B-49A8-97F1-AFBAC7383839 Q30217177-A9C24E66-1510-4FB0-8A5E-CF15F6325EB7 Q30427591-763ED6E4-2D4A-4102-9499-10528209DCD3 Q30558268-B89C5C45-DFF1-4959-BDB8-B395E5119AA3 Q33351971-72188D81-5594-4D21-AB9E-5E5BA77C46C8 Q33614545-588FEE50-9DE6-43CE-BA84-CB1A5D8C3161 Q33676444-DED02009-0DC4-48DD-A19B-DF7638CCB7F6 Q33755041-B4FABC3C-97BB-4CDB-861E-C753B258332E Q33920185-1194CF16-50A9-4CF4-BE50-91C9832C903C Q34045678-47A1A72B-2130-4D57-8D04-DBFB4B3C404A Q34092753-16925FCC-CC9F-4E33-8B4D-8546C5666C22 Q34111792-B2E3EC1F-C311-4400-82F0-6B56CC825BE9 Q34228487-E9CA8E7C-8A04-4FD1-8C40-A13BA20B512F Q35076961-6A8EC000-434F-4DE8-A0D6-395E6AFC6B50 Q35194202-7D192792-CD60-4C3D-8596-47A3393993CC Q35851801-5D92781D-46AF-401F-93C4-2AF5F48D8B4E Q35946943-40E86A96-11EA-4568-BB3E-BCCFC0F669E3 Q35953762-B8EFB4D2-9CBD-49DC-9BEB-9CE958E98B34 Q36010016-0702F9CD-AE41-49E1-ADDB-FCB42CB5C7E4 Q36086236-DD24FED1-5C25-45DD-BDF6-0D0AA8E3C142 Q36315159-6B404C89-5BB3-47E1-AF2F-535E3EE81D27 Q36464587-76B00D80-D123-44BF-AFC5-6329DA6DD620 Q36488876-85AFF103-F8EA-48A9-BEBE-9F5F2FE4E16D Q36667964-6550086C-DA45-4528-8BFF-976DC97F1D5D Q36716920-8172F6E4-00D8-4124-952B-DCA55A9FAA18 Q37033291-275E7FC4-EA23-4FF9-B9D4-5735237C588B Q37094429-D16974DC-C2C5-4C15-BC5C-CAA275B509E8 Q37451959-288E2F87-DE87-42EA-A0BF-C62FFC8A447C Q38096490-6EF3DB82-BB88-4BB6-9363-11E3B11E0386 Q38255634-54B0A0A0-B0F0-4A18-A8BC-66AD6E56671A Q38266413-14A99EF3-E0B4-404F-940F-127783FF3F43 Q38287790-DB9E958F-A709-478A-A44D-B291E403AFD6 Q41812230-F6304C6B-FC4B-43AF-9477-44C79048A8C2

P2860

Alphavirus replicon particles as candidate HIV vaccines.

http://www.wikidata.org/entity/Q34743830

description

2002 nî lūn-bûn

@nan

2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Alphavirus replicon particles as candidate HIV vaccines.

@ast

Alphavirus replicon particles as candidate HIV vaccines.

@en

Alphavirus replicon particles as candidate HIV vaccines.

@nl

type

label

Alphavirus replicon particles as candidate HIV vaccines.

@ast

Alphavirus replicon particles as candidate HIV vaccines.

@en

Alphavirus replicon particles as candidate HIV vaccines.

@nl

prefLabel

Alphavirus replicon particles as candidate HIV vaccines.

@ast

Alphavirus replicon particles as candidate HIV vaccines.

@en

Alphavirus replicon particles as candidate HIV vaccines.

@nl

P1433

Q34743830-79C1A5F6-D671-4B4B-A0A5-3E60FCCB5176

P1476

Q34743830-AFFEC82E-872B-4A4F-96DE-A7BEA86B4598

P2093

Q34743830-2B17B874-E6E4-4953-984B-9AF19DA52CDD

Q34743830-30C8DC5B-C70D-411E-AF5E-B372466AAC10

Q34743830-3B573AC1-79B5-44C9-8FC5-41E8CC3B12FA

Q34743830-65119AC4-E6B8-40D8-B030-E422FE4F191C

Q34743830-6E6BF163-9805-4B9B-ABD4-5F678923EA4F

Q34743830-7DEEF25A-5799-4648-872A-6CDC7AB33AD1

Q34743830-83793B17-A65B-4ABC-8608-632773F0579B

Q34743830-8A49C292-6F31-469C-9C50-69A7BF8531DD

Q34743830-95848D28-B3B9-44E3-A054-8C44329CB7DD

Q34743830-95CF1D7D-894C-4EE7-A331-3173D97EB37D

P304

Q34743830-B3F35BCA-6361-4C0B-B491-56268DBCD0F5

P31

Q34743830-0CFE33B4-CE4C-4AF8-9D3B-CB26F56B0636

P356

Q34743830-0AD0A6BD-6F40-4D67-8BDE-CFCA1CF046E4

P433

Q34743830-CE551D20-7D7D-41B5-B336-2805A0594730

P478

Q34743830-9F576C2B-5CC3-4081-8AE7-A32F7918FCBA

P50

Q34743830-07F545E5-861E-4C3B-ACE1-276DACC48BFD

Q34743830-8224049A-BB84-43BD-A359-E6FE413C5329

Q34743830-AF45C183-BB7E-4905-9723-2A58B8803244

P577

Q34743830-01D23479-04F4-4206-9786-01677F60408F

P5875

Q34743830-6179BA89-0139-4C9F-A66E-BC9485F1CA3A

P698

Q34743830-473B7E5D-553B-4DA5-BE2B-48BB7060D3D7

P921

Q34743830-480D8682-4E19-49C7-A6D0-B48410785B25

P356

P1433

P1476

Alphavirus replicon particles as candidate HIV vaccines.

@en

P2093

Ande West

http://www.w3.org/2001/XMLSchema#string

Chad Cecil

http://www.w3.org/2001/XMLSchema#string

Chris Walker

http://www.w3.org/2001/XMLSchema#string

Elizabeth Reap

http://www.w3.org/2001/XMLSchema#string

Gene MacDonald

http://www.w3.org/2001/XMLSchema#string

Jeff Frelinger

http://www.w3.org/2001/XMLSchema#string

Kathryn McGrath

http://www.w3.org/2001/XMLSchema#string

Li-Hua Ping

http://www.w3.org/2001/XMLSchema#string

Martha Collier

http://www.w3.org/2001/XMLSchema#string

Mary Connell

http://www.w3.org/2001/XMLSchema#string

P304

209-211

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15216540212657

http://www.w3.org/2001/XMLSchema#string

P433

4-5

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Ronald Swanstrom

David C Montefiori

Carolyn Williamson

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11257922

http://www.w3.org/2001/XMLSchema#string

P698

12120997

http://www.w3.org/2001/XMLSchema#string

P921